Greg Dwyer

Company: Orum Therapeutics

Job title: SVP, Head of Business Development

Seminars:

Effectively & Efficiently Structuring Deal Processes as a Small ADC or Radiopharmaceutical Company 1:40 pm

Discussing the panel’s experiences executing and performing due diligence for noteworthy ADC and radiopharma, mergers, and licensing deals Sharing pharma’s expectation for data packages and deal process; how to differentiate in the buy/sell dynamic Outlining creative partnerships and deal structures that create effective BD&L in 2024Read more

day: Day Two - PM

Panel Discussion: DACs, Protacs & Molecular Glues: Why is ADC Technology What Protein Degradation Needs? 8:15 am

Discussing mechanistic differences across protein degradation payloads, their therapeutic role, and liabilities Demonstrating a protein degradation therapeutic window, and selective delivery with antibodies Understanding why protein degradation experts believe ADC technology is neededRead more

day: Day Two -AM

TPD²: Cell Selective Degradation 8:45 am

Improving upon efficacy, safety, and half-life of conventional targeted protein degraders Orum’s proprietary Dual-precision Targeted Protein Degradation (TPD² ™) approach uses antibodies to precisely deliver small molecule targeted protein degrader payloads to cancer cells Discussing collaboration possibilities across TPD² and TPS² platforms and programsRead more

day: Day Two -AM